MARKET

GRTX

GRTX

GALERA THERAPEUTICS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.64
-0.31
-2.83%
Opening 10:38 12/02 EST
OPEN
10.81
PREV CLOSE
10.95
HIGH
11.13
LOW
10.64
VOLUME
756
TURNOVER
--
52 WEEK HIGH
19.50
52 WEEK LOW
5.58
MARKET CAP
265.48M
P/E (TTM)
-3.6793
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020. The pre-recorded fireside chat can be accessed beginning November 23, 2020, from the Investors page of Galera’s website, investors.galeratx.com, and will remain available for 60 days following the conference.About Galera TherapeuticsGalera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial to assess its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication. It is also being studied in the EUSOM Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, the AESOP Phase 2a trial to assess its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer, and a Phase 2 trial in hospitalized patients who are critically ill with COVID-19. A pilot Phase 1/2 trial of avasopasem in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer has completed enrollment and reported interim results, with follow-up ongoing. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera’s second dismutase mimetic product candidate, GC4711, is being developed specifically to augment the anti-cancer efficacy of SBRT, and is currently being studied in the GRECO-1 Phase 1/2 clinical trial in combination with SBRT in patients with non-small cell lung cancer. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.Investor Contacts: Christopher Degnan Galera Therapeutics, Inc. 610-725-1500 cdegnan@galeratx.comJennifer Porcelli Solebury Trout 646-378-2962 jporcelli@soleburytrout.comMedia Contact: Heather Anderson 6 Degrees 919-827-5539 handerson@6degreespr.com
GlobeNewswire · 11/20 13:00
Galera down 6% on disappointing data on lead drug in pancreatic cancer
Thinly traded micro cap Galera Therapeutics ([[GRTX]] -5.8%) slips on more than a 6x surge in volume, albeit on only 394K shares, in reaction to preliminary results from a dose-escalation
Seekingalpha · 10/27 19:42
Galera Therapeutics Announces Interim Data From Pilot Phase 1/2 Trial Of GC4419 In Combination With Stereotactic Body Radiation Therapy Showing 'Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer'
Initial results from pilot Phase 1/2 clinical trial in patients with locally advanced pancreatic cancer presented during virtual ASTRO Annual Meeting First trial to evaluate anti-cancer activity of one of Galera’s
Benzinga · 10/27 19:01
NGL, EXAS, HOG and KALA among midday movers
Gainers: Scholar Rock (SRRK) +87%.Weidai (WEI) +60%.1847 Goedeker (GOED) +43%.Harley-Davidson (HOG) +27%.Synalloy (SYNL) +25%.Exact Sciences (EXAS) +22%.Harbor Custom Development (HCDI) +21%.TuanChe (TC) +20%.Unifi (UFI) +19%.CASI Pharmaceuticals (CASI) +18%.Losers: Catabasis Pharmaceuticals (CATB) -70%.Liquid Media Group (YVR) -21%.Knoll
Seekingalpha · 10/27 16:43
Scholar Rock, Exact Sciences leads healthcare gainers; Catabasis Pharmaceuticals, Galera Therapeutics among major losers
Gainers: Scholar Rock Holding (SRRK) +80%, Exact Sciences (EXAS) +18%, CHF Solutions (CHFS) +17%, CASI Pharmaceuticals (CASI) +13%, Prelude Therapeutics (PRLD) +8%.Losers: Catabasis Pharmaceuticals (CATB) -68%, Galera Therapeutics (GRTX) -14%, Genfit (GNFT) -13%, Kala Pharmaceuticals (KALA) -9%, GeoVax Labs (GOVX) -7%.
Seekingalpha · 10/27 15:02
The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 26)
Benzinga · 10/27 12:24
SAP, DNKN, CODX and NNDM among midday movers
Gainers: Document Security Systems (DSS) +43%.Muscle Maker (GRIL) +39%.Lianluo Smart (LLIT) +35%.Co-Diagnostics (CODX) +19%.SilverSun Technologies (SSNT) +18%.Mid-Con Energy Partners (MCEP) +18%.Galera Therapeutics (GRTX) +15%.Dunkin' Brands (DNKN) +15%.GeoVax Labs (GOVX) +14%.Selecta Biosciences (SELB) +13%.Losers: BioSig
Seekingalpha · 10/26 16:38
Galera Therapeutics' lead asset shows survival benefit in pancreatic cancer study
Interim data from first 19 patients in Phase 1/2 trial evaluating Galera Therapeutics' (GRTX) lead candidate avasopasem manganese (GC4419) in combination with stereotactic body radiation therapy ((SBRT)), showed improvement in overall survival ((OS))
Seekingalpha · 10/26 11:20
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GRTX. Analyze the recent business situations of GALERA THERAPEUTICS, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GRTX stock price target is 19.25 with a high estimate of 30.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 49
Institutional Holdings: 18.84M
% Owned: 75.52%
Shares Outstanding: 24.95M
TypeInstitutionsShares
Increased
7
61.95K
New
7
65.09K
Decreased
14
32.84K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
+0.56%
Key Executives
Chairman/Independent Director
Michael Powell
President/Chief Executive Officer/Director
J. Mel Sorensen
Chief Financial Officer
Christopher Degnan
Chief Operating Officer
Robert Beardsley
Chief Accounting Officer
Joel Sussman
Other
Arthur Fratamico
Other
Jon Holmlund
Director
Emmett Cunningham
Independent Director
Lawrence Alleva
Independent Director
Kevin Lokay
Independent Director
Linda West
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GRTX
Galera Therapeutics, Inc is a clinical stage biopharmaceutical company. It is focused on developing and commercializing a pipeline therapeutics to transform radiotherapy in cancer. It is focused on leveraging capability in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy. Its pipeline product are GC4419 and GC4711. Its lead product candidate GC4419, is a potent selective small molecule dismutase mimetic. The Company is initially focused on developing GC4419 for the reduction of severe oral mucositis (SOM). GC4419, is also known as avasopasem manganese, and has completed two clinical trials. The Company’s second dismutase mimetic product candidate is GC4711. The Company is specifically targeting GC4711, an analog of GC4419, to increase the anti-cancer efficacy of SBRT. It is in Phase 1 development both as a lyophilized product for intravenous administration given as an oral capsule.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Galera Therapeutics Inc stock information, including NASDAQ:GRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GRTX stock methods without spending real money on the virtual paper trading platform.